# Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

> **NCT05358639** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 36 (estimated)

## Conditions studied

- High Grade Serous Carcinoma
- Triple Negative Breast Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib tablet
- **DRUG:** Navitoclax

## Key facts

- **NCT ID:** NCT05358639
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-09
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-04-28
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358639, "Combination of Olaparib and Navitoclax in Women with HGSC and TNBC". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05358639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*